Cosmo Bio Company,Limited (TYO:3386)

Cosmo Bio Company,Limited Balance Sheet

Financials in millions JPY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	3,468	2,747	2,393	2,826	3,036	3,255
Short-Term Investments	600	199	300	199	-	300
Cash & Short-Term Investments	4,068	2,946	2,693	3,025	3,036	3,555
Cash Growth	27.44%	9.40%	-10.97%	-0.36%	-14.60%	9.08%
Accounts Receivable	2,601	3,085	3,002	2,851	2,798	2,710
Receivables	2,601	3,085	3,002	2,851	2,798	2,710
Inventory	1,006	1,100	1,065	1,038	1,134	863
Other Current Assets	255	310	469	188	168	182
Total Current Assets	7,930	7,441	7,229	7,102	7,136	7,310
Property, Plant & Equipment	799	862	701	572	577	599
Long-Term Investments	3,948	4,144	3,592	3,013	2,397	1,954
Other Intangible Assets	165	167	162	155	171	182
Long-Term Deferred Tax Assets	-	46	37	29	31	25
Other Long-Term Assets	2	2	2	1	1	2
Total Assets	12,844	12,662	11,723	10,872	10,313	10,072

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	622	806	747	639	573	592
Short-Term Debt	20	20	20	20	20	20
Current Income Taxes Payable	119	439	203	294	242	319
Other Current Liabilities	320	157	196	170	203	162
Total Current Liabilities	1,081	1,422	1,166	1,123	1,038	1,093
Pension & Post-Retirement Benefits	694	655	618	555	507	501
Long-Term Deferred Tax Liabilities	-	523	311	87	66	92
Other Long-Term Liabilities	721	107	74	83	86	68
Total Liabilities	2,496	2,707	2,169	1,848	1,697	1,754

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	918	918	918	918	918	918
Additional Paid-In Capital	1,273	1,267	1,263	1,261	1,260	1,258
Retained Earnings	6,015	5,880	5,891	5,805	5,560	5,274
Treasury Stock	-353	-379	-317	-194	-216	-239
Comprehensive Income & Other	1,904	1,687	1,212	653	529	575
Total Common Equity	9,757	9,373	8,967	8,443	8,051	7,786
Minority Interest	591	582	587	581	565	532
Shareholders' Equity	10,348	9,955	9,554	9,024	8,616	8,318
Total Liabilities & Equity	12,844	12,662	11,723	10,872	10,313	10,072

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	20	20	20	20	20	20
Net Cash (Debt)	4,048	2,926	2,673	3,005	3,016	3,535
Net Cash Growth	27.62%	9.46%	-11.05%	-0.36%	-14.68%	9.14%
Net Cash Per Share	712.90	514.49	459.61	515.57	519.52	608.56
Filing Date Shares Outstanding	5.7	5.67	5.71	5.84	5.81	5.79
Total Common Shares Outstanding	5.7	5.67	5.73	5.84	5.81	5.79
Working Capital	6,849	6,019	6,063	5,979	6,098	6,217
Book Value Per Share	1712.38	1651.94	1564.87	1446.87	1384.92	1344.30
Tangible Book Value	9,592	9,206	8,805	8,288	7,880	7,604
Tangible Book Value Per Share	1683.42	1622.50	1536.60	1420.30	1355.51	1312.88

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 16, 2026

Data Sources Report a data error